n Southern African Journal of HIV Medicine - Paediatric antiretroviral pharmacology




Half of the ARV agents available worldwide have paediatric approval, but many are without ideal paediatric formulations. Pharmacokinetic differences in paediatric populations require careful attention to dosing and concomitant therapies. Importantly, ARV therapy can be limited by short-term and long-term toxicity and drug interactions. <br>Low-cost, sustained and consistent access to ARV therapy is necessary to combat the HIV epidemic. For optimal response &gt; 90 - 95% adherence to ARVs is required. This requires that extensive education and support resources be provided in addition to the ARV medications themselves. Paediatric patients receiving ARV therapy require ongoing monitoring to ensure tolerability, dose adjustments with advancing age, acceptability and therapeutic success.


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error